In the phase 3 MONALEESA-2 trial, ribociclib plus letrozole or tamoxifen significantly prolonged PFS in postmenopausal ERα+ breast cancers previously untreated with systemic therapy [146,147]. The gene discussed is ESR1; the disease is breast cancer.